Evidence · Research paper
Association of High-Dose Erythropoietin With Circulating Biomarkers and Neurodevelopmental Outcomes Among Neonates With Hypoxic Ischemic Encephalopathy: A Secondary Analysis of the HEAL Randomized Clinical Trial.
- Anaemia and transfusion
- Hypoxic-ischaemic encephalopathy and cooling
- Jaundice and haematology
- Medical
- Neurodevelopmental follow-up
- Neurology
Summary
Preplanned secondary analysis of the US multicentre HEAL randomised trial of high-dose erythropoietin as an adjunct to therapeutic hypothermia in term and near-term infants with moderate or severe hypoxic ischaemic encephalopathy. It examined whether erythropoietin altered circulating inflammatory and brain injury biomarkers, and whether a biomarker panel improved prediction of death or neurodevelopmental impairment at 2 years. Erythropoietin did not reduce biomarkers of neuroinflammation or brain injury. Six plasma biomarkers modestly improved outcome prediction beyond clinical data available at birth.
Summary written for NICUlearn. Always read the original.
- Licence:
- Open (Creative Commons)
The full text of this openly licensed paper is available to NICUlearn members, and Neeky can answer questions from it.
Guidelines are shown for education. Follow your unit's own guidance and senior advice.